These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 3782958)
1. Clinical significance of statistical discrimination employing serum TA-4, TPA, and CEA levels in uterine cervical cancer. Yabushita H; Ogawa A; Masuda T; Noguchi M; Nakanishi M; Ishihara M Nihon Sanka Fujinka Gakkai Zasshi; 1986 Oct; 38(10):1770-6. PubMed ID: 3782958 [TBL] [Abstract][Full Text] [Related]
2. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms]. Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349 [TBL] [Abstract][Full Text] [Related]
3. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449 [TBL] [Abstract][Full Text] [Related]
4. [Clinical usefulness of serum TPA, IAP and CEA levels in gynecological cancer]. Saitoh S; Nakanishi A; Noda T; Ando Y; Kamamoto Y; Moriyama I; Ichijo M Nihon Gan Chiryo Gakkai Shi; 1984 Aug; 19(7):1496-504. PubMed ID: 6520506 [No Abstract] [Full Text] [Related]
5. Clinical significance of different serum tumor markers in gynecological malignancies. Paulick R; Caffier H; Horner G; Lang K; Filbry E Cancer Detect Prev; 1985; 8(1-2):115-20. PubMed ID: 4064031 [TBL] [Abstract][Full Text] [Related]
6. [A comparative evaluation of tumor markers (TPA and CEA) in various malignant neoplasms at an advanced stage]. Meregalli M; Antoniazzi V; Torchio G; Colombo E; Bocchi M; Sonzini E; Lino S Minerva Med; 1989 Apr; 80(4):345-7. PubMed ID: 2725935 [TBL] [Abstract][Full Text] [Related]
7. Human tissue polypeptide antigen in breast cancer. Nemoto T; Constantine R; Chu TM J Natl Cancer Inst; 1979 Dec; 63(6):1347-50. PubMed ID: 292806 [TBL] [Abstract][Full Text] [Related]
8. [A clinical study on multiple tumor markers following therapy in patients with uterine cervical carcinoma]. Hiura M; Yorishima M; Tanaka M; Yokoyama T; Myoga H; Chiba T; Nakanishi Y Nihon Sanka Fujinka Gakkai Zasshi; 1990 May; 42(5):471-8. PubMed ID: 2373919 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, and squamous cell carcinoma antigen in the detection of cervical cancers. Lam CP; Yuan CC; Jeng FS; Tsai LC; Yeh SH; Ng HT Zhonghua Yi Xue Za Zhi (Taipei); 1992 Jul; 50(1):7-13. PubMed ID: 1326391 [TBL] [Abstract][Full Text] [Related]
10. [Prediction of the recurrence of squamous cell carcinoma of the uterine cervix by monitoring serum TA-4]. Oishi T; Maruo T; Yamasaki M; Mochizuki M Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):799-806. PubMed ID: 3598275 [TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of tumor markers in breast cancer patients]. Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106 [TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin. Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix. Volgger B; Aspisirengil C; Genser-Krimbacher E; Ciresa-Koenig A; Daxenbichler G; Fuchs D; Windbichler G; Marth C Cancer Lett; 2008 Apr; 262(2):183-9. PubMed ID: 18226853 [TBL] [Abstract][Full Text] [Related]
15. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]. Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513 [TBL] [Abstract][Full Text] [Related]
16. Differential immunocytochemical localization of tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) in breast cancer. Björklund V; Björklund B Cancer Detect Prev; 1983; 6(1-2):193-8. PubMed ID: 6883380 [TBL] [Abstract][Full Text] [Related]
17. [A study on tumor marker of tissue-polypeptide-antigen (TPA) in gynecologic malignancies]. Nakajima H; Hirata T; Norisugi T; Furuno K; Ikehata N; Utsunomiya A; Kobayashi K; Negishi Y; Akiya K Nihon Sanka Fujinka Gakkai Zasshi; 1984 Oct; 36(10):1877-83. PubMed ID: 6094688 [TBL] [Abstract][Full Text] [Related]
18. Combined use of carcinoembryonic antigen and tissue polypeptide antigen in oncologic therapy and surveillance. Lüthgens M; Schlegel G Cancer Detect Prev; 1983; 6(1-2):51-9. PubMed ID: 6883393 [TBL] [Abstract][Full Text] [Related]
19. [Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers]. Ruibal A; Durán P; Lafuerza A; Bodi R; Solé LA; Rubio D; Ibarz L; De Torres JA; Domenech-Torné FM; Salvador L Rev Esp Oncol; 1984; 31(3):409-14. PubMed ID: 6546169 [TBL] [Abstract][Full Text] [Related]
20. [Tumor markers of pancreatic cancer]. Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]